Absci (NASDAQ:ABSI) used a presentation at the Leerink Partners Global Healthcare Conference to outline how the company is applying its internal AI-driven drug design platform to generate “differentiated” antibody assets, while advancing its own lead clinical program, ABS-201, in androgenetic alopecia (AGA) and endometriosis. AI platform focus: “unaddressable” targets and partnerable assets Absci’s leadership described [...]
Absci Highlights AI Antibody Platform, ABS-201 Hair-Loss Trial Milestones at Leerink Conference
